Persistent Empiric COPD Diagnosis and Treatment After Pulmonary Function Test Showed No Obstruction

Respir Care. 2016 Sep;61(9):1192-200. doi: 10.4187/respcare.04647. Epub 2016 May 10.

Abstract

Background: Health-care providers often diagnose and empirically treat COPD without a confirmative pulmonary function test (PFT) or even despite a PFT that is not diagnostic of obstructive lung disease. We hypothesized that a portion of patients continue to carry a persistent empiric COPD diagnosis and receive treatment with bronchodilators and inhaled steroids after a PFT shows no obstruction.

Methods: We retrospectively reviewed single PFT sessions with both spirometry and plethysmography in 1,805 subjects. We included subjects who had a normal PFT or a restrictive ventilatory defect. Persistent empiric COPD diagnosis and treatment were defined when subjects with normal PFTs or a restrictive ventilatory defect continued to carry a health-care provider COPD diagnosis or receive treatment with bronchodilators and/or inhaled glucocorticoids, respectively, after a PFT showed no obstruction.

Results: One quarter of subjects with FEV1/FVC ≥ lower limit of the normal range had nonspecific PFT abnormalities. We included 473 subjects with normal PFTs and 382 with a restrictive ventilatory defect (n = 855). Persistent empiric COPD diagnosis (60 of 855, 7% prevalence) was associated with current (odds ratio [OR] = 44.7, P < .001) and former smoking (OR = 17.3, P < .001) and older age (OR = 1.03/y, P = .005). Persistent empiric treatment (208 of 855, 24%) was associated with empiric COPD diagnosis (OR = 24.6, P < .001), female sex (OR = 1.75, P = .002), current (OR = 2.04, P = 0.040) and former smoking (OR = 1.53, P = 0.029), interstitial lung disease (OR = 2.09, P = .001), other respiratory diagnosis (OR = 3.17, P < .001), and obstructive sleep apnea (OR = 1.79, P = .006).

Conclusions: Persistent empiric COPD diagnosis was 7%, but persistent empiric treatment was common.

Keywords: COPD; diagnosis; diagnostic errors; plethysmography; pulmonary function tests; spirometry.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Bronchodilator Agents / therapeutic use*
  • Diagnostic Errors*
  • Female
  • Forced Expiratory Volume
  • Glucocorticoids / therapeutic use*
  • Humans
  • Lung Diseases, Interstitial / physiopathology
  • Male
  • Medical Audit
  • Middle Aged
  • Plethysmography
  • Pulmonary Disease, Chronic Obstructive / diagnosis*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Retrospective Studies
  • Sex Factors
  • Sleep Apnea, Obstructive / physiopathology
  • Smoking / physiopathology
  • Spirometry
  • Vital Capacity

Substances

  • Bronchodilator Agents
  • Glucocorticoids